🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma

Recruitingn/aAges 18 Years - 75 YearsAllGuangxi Medical University
NCT06405321 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This multicenter retrospective study which included patients with hepatocellular carcinoma (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histologically or clinically confirmed diagnosis of HCC. * Patients who received conversion or neoadjuvant therapy as initial treatment, including hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), or radiotherapy. * Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1. * With Child-Pugh 5\~7 scores. Exclusion Criteria: * Concurrent with other malignancies within 5 years. * Incomplete medical data. * Follow-up time less than 3 months.
💊

What it tests

  • Conversion or neoadjuvant therapy.
📍

Where

1 site
Jian-Hong Zhong
Nanning, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy